Every 10-Q that Caris Life Sciences, Inc. (CAI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CAI filings page.
Caris Life Sciences, Inc. reported higher results for the quarter ended June 30, 2026. Total revenue was 263,712 (amounts in thousands), up from 181,398 a year earlier, driven by molecular profiling services of 252,254, while pharma research and development services declined to 11,458.
Costs and operating expenses were 236,786, producing income from operations of 26,926 versus a prior-year operating loss of 17,989. A 25,232 loss on extinguishment of the 2023 term loan and interest expense of 9,228 led to a small net loss of 637 for the quarter and 1,147 year-to-date, compared with 71,790 and 174,370 in 2025.
As of June 30, 2026, Caris held cash, cash equivalents and restricted cash of 692,745 and short-term marketable securities of 102,200, against long-term indebtedness of 392,973. Operating activities provided 61,353 of cash in the first half. The company also authorized a 100.0 million share repurchase program and retired 1,000,000 shares for 17.9 million.
Caris Life Sciences reported strong Q1 2026 growth with total revenue of $216.174 million, up from $120.915 million a year earlier, driven mainly by molecular profiling services. The company generated income from operations of $5.282 million versus a prior operating loss and kept net loss nearly flat at $0.510 million.
Adjusted EBITDA improved to $26.2 million, and free cash flow turned positive at $22.5 million. Caris ended the quarter with $825.705 million in cash, cash equivalents, restricted cash and marketable securities and had $400.0 million of term loan debt outstanding before refinancing after quarter-end.
Caris Life Sciences (CAI) filed its Q3 2025 10‑Q. Revenue rose to $216.8 million from $101.6 million a year ago, driven mainly by molecular profiling services ($207.6 million). Operating results improved to income of $32.6 million from a loss, with net income of $24.3 million versus a prior-year net loss.
For the nine months, revenue reached $519.1 million (from $282.3 million), while the company recorded a net loss of $150.0 million, reflecting non-operating items including fair value changes and financing effects. Cash, cash equivalents, and restricted cash were $757.0 million at period end, supporting total assets of $984.6 million.
Following its June IPO at $21.00 per share, preferred shares and 2025 convertible notes converted into common stock, and certain warrants were exercised. Shareholders’ equity improved to $478.4 million from a prior deficit, with 282.1 million common shares outstanding as of September 30, 2025.
Caris Life Sciences completed a major financing and reported strong revenue growth while remaining loss-making. Total revenue for the three months ended June 30, 2025 was $181.4 million, up from $100.0 million a year earlier, led by molecular profiling services of $162.9 million. The company closed a pre-IPO financing on April 1, 2025 aggregating $167.7 million and completed an initial public offering on June 20, 2025 that produced net proceeds of $459.5 million plus a $68.9 million over-allotment, contributing to a period-end cash balance of $722.7 million. Net loss was $71.8 million for the quarter and $174.4 million for the six months ended June 30, 2025, with significant other expense items including fair-value adjustments and increased interest expense. All outstanding redeemable convertible preferred shares converted into common stock upon the IPO.